Solid Biosciences Inc.: RA CAPITAL MANAGEMENT, L.P. amends Schedule 13D stake filing
Open the sourceReported by SEC EDGAR SCHEDULE 13D, sec.gov, 6 November 2026, by SEC EDGAR SCHEDULE 13D
30
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
RA Capital Management amended its Schedule 13D filing on Solid Biosciences Inc., updating its disclosed stake in the gene-therapy developer with the SEC under accession number 0001346824-26-000255. The amendment signals a change in the investor's position or intent regarding its holding. Investors will watch for further 13D amendments to gauge whether RA Capital is adding to or trimming its stake.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13D's report. It can get details wrong, so check the source.
Named in this story
Solid Biosciences Inc., RA Capital Management, L.P.